Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Lupus

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0961203309360544PMID 20353977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome

  2010cited by this paper
• Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

  2009cited by this paper
• In vivo inhibition of antiphospholipid antibody‐induced pathogenicity utilizing the antigenic target peptide domain I of β2‐glycoprotein I: proof of concept

  2009cited by this paper
• Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

  2008cited by this paper
• International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS)

  2008cited by this paper
• A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies.

  2007cited by this paper
• Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43.

  2007cited by this paper
• Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change.

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli

  2006cited by this paper
• Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway.

  2006cited by this paper
• Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V.

  2006cited by this paper
• Thrombotic Risk Factors In Primary Antiphospholipid Syndrome: A 5-Year Prospective Study

  2005cited by this paper
• The Binding Site in β2-Glycoprotein I for ApoER2′ on Platelets Is Located in Domain V*

  2005cited by this paper
• Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies.

  2005cited by this paper
• IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.

  2005cited by this paper
• beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

  2004cited by this paper
• Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation

  2004cited by this paper
• Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

  2004cited by this paper
• Antiphospholipid antibodies: immunological aspects.

  2004cited by this paper
• A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo.

  2004cited by this paper
• Anti-CD 40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

  2004cited by this paper
• How do antiphospholipid antibodies bind beta2-glycoprotein I?

  2003cited by this paper
• Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome.

  2003cited by this paper
• Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.

  2003cited by this paper
• How do antiphospholipid antibodies bind β2-glycoprotein I?

  2003cited by this paper
• Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies.

  2003cited by this paper
• Prevalence and Clinical Correlations of Antibodies Against Six β2-Glycoprotein-I-Related Peptides in the Antiphospholipid Syndrome

  2003cited by this paper
• Thrombogenic Effects of Antiphospholipid Antibodies Are Mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin

  2001cited by this paper
• Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources.

  2000cited by this paper
• Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.

  1999cited by this paper
• Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding.

  1998cited by this paper
• Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

  1998cited by this paper
• Target Recognition of β2-Glycoprotein I (β2GPI)-Dependent Anticardiolipin Antibodies: Evidence for Involvement of the Fourth Domain of β2GPI in Antibody Binding

  1998cited by this paper
• Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI

  1998cited by this paper
• Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

  1998cited by this paper
• Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system.

  1996cited by this paper
• Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach.

  1995cited by this paper
• The management of thrombosis in the antiphospholipid-antibody syndrome.

  1995cited by this paper
• Effect of Human IgG Antiphospholipid Antibodies on an In Vivo Thrombosis Model in Mice

  1994cited by this paper
• Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

  1990cited by this paper
• Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

  1990cited by this paper
• Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

  1990cited by this paper
• Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus.

  1988cited by this paper

• Quantification of Antiphospholipid Antibodies: The Importance of Using an Appropriate Methodology for Each Clinical Profile

  2023cites this paper
• Effects of anti‐beta 2‐glycoprotein 1 antibodies and its association with pregnancy‐related morbidity in antiphospholipid syndrome

  2021cites this paper
• Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome—What is the evidence?

  2021cites this paper
• Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding

  2021cites this paper
• The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS

  2020cites this paper
• The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome

  2020cites this paper
• The IgA Isotype of Anti-β2 Glycoprotein I Antibodies Recognizes Epitopes in Domains 3, 4, and 5 That Are Located in a Lateral Zone of the Molecule (L-Shaped)

  2019cites this paper
• Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome.

  2019cites this paper
• PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome

  2018cites this paper
• Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies.

  2018cites this paper
• Lysine residues control the conformational dynamics of beta 2-glycoprotein I.

  2018cites this paper
• Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts

  2018cites this paper
• Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation

  2017cites this paper
• Laboratory Diagnostics of Antiphospholipid Syndrome

  2017cites this paper
• Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion

  2017cites this paper
• Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

  2017cites this paper
• The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis.

  2016cites this paper
• β2GP1, Anti-β2GP1 Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome

  2016cites this paper
• Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS

  2015cites this paper
• Cardiac injury in lupus

  2014cites this paper
• Reactivity against the Five Domains of β 2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

  2014cites this paper
• New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies

  2014cites this paper
• Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

  2013cites this paper
• 4 Antiphospholipid Antibodies – Detection and Clinical Importance

  2012cites this paper
• The Michael Mason Prize: Pathogenic antiphospholipid antibodies, stressed out antigens and the deployment of decoys.

  2012cites this paper
• Antiphospholipid Antibodies – Detection and Clinical Importance

  2012cites this paper
• Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes.

  2012cites this paper
• Epitopic Peptides Identified by LC–ELISA and LC–MS

  2011cites this paper
• Effects Of Antiphospholipid Antibodies On Trophoblast-Mediated Angiogenesis And Vascular Remodeling

  2011cites this paper
• Phospholipid inhibitors

  2011cites this paper
• Pathogenesis of antiphospholipid syndrome: understanding the antibodies

  2011cites this paper
• Patient‐derived monoclonal antibodies directed towards beta2 glycoprotein‐1 display lupus anticoagulant activity

  2011cites this paper